title: Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.
authors.affiliation: Division of Hematology, Brigham and Women's Hospital, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Maureen M
authors.initials: MM
authors.lastname: Okam
authors.affiliation: Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.
authors.forename: Erica B
authors.initials: EB
authors.lastname: Esrick
authors.affiliation: Division of Hematology, Brigham and Women's Hospital, Boston, MA.
authors.forename: Elyse
authors.initials: E
authors.lastname: Mandell
authors.affiliation: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Federico
authors.initials: F
authors.lastname: Campigotto
authors.affiliation: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA.
authors.forename: Donna S
authors.initials: DS
authors.lastname: Neuberg
authors.affiliation: Division of Hematology, Brigham and Women's Hospital, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Benjamin L
authors.initials: BL
authors.lastname: Ebert
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000188:drug therapy*; D000986:Antisickling Agents / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage*; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage*; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D000077337:Vorinostat
chemical_list: D000986:Antisickling Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat; D006918:Hydroxyurea